replaced by moxifloxacin to the standard regimen. The efficacy of the regimens was compared 38 to the standard regimen for bacterial CFU count elimination and removal of persistent tubercle 39 bacilli evaluated using culture filtrate (CF) derived from M. tuberculosis strain H37Rv. We 40 also measured disease relapse rates. Moxifloxacin-isoniazid substituted regimen achieved total 41 organ CFU count clearance at 11 weeks post-treatment, faster than standard regimen (14 42 weeks), and with a 34% lower relapse rate. Moxifloxacin-ethambutol substituted regimen was 43 similar to standard regimens in these regards. Importantly, neither moxifloxacin-substituted 44 regimens nor the standard regimen could remove CF-dependent persistent bacilli. Evaluation 45 of CF-dependent persistent M. tuberculosis requires confirmation in human studies, and has 46 implications in future drug design, testing and clinical applications. 47
INTRODUCTION 54 TB caused by Mycobacterium tuberculosis remains a leading cause of mortality worldwide (1). 55
Current combination antimicrobial regimens require a prolonged 6-month treatment period. 56
This long regimen leads to poor patient compliance which gives rise to the emergence of drug 57 resistance and high relapse rates (2). Substitution of moxifloxacin (an 8-methoxy 58 fluoroquinolone) for drugs in the contemporary anti-TB regimen has shown promise for 59
For assessment of treatment efficacy, a sample of 4 mice was sacrificed at 2, 4, and 6 weeks 109 and 8 mice were sacrificed at 8, 11 and 14 weeks of treatment (Table 1) . Mouse lungs and 110 spleens were transferred into 2 ml tubes each containing 1 ml sterile distilled water and 2 mm 111 diameter glass beads, followed by homogenizing using a reciprocal shaker (Thermo Hybaid 112 Ltd) for 40 seconds at 6.5 speed. The CFU counts from each lung and spleen were performed 113 using serial dilutions of the homogenates to plate on 7H11 agar plates. 114
At 11 and 14 weeks of treatment, the entire organ homogenates from the 8 mice were aliquoted 115 equally into three tubes which were used 1. The CFU counting by plating out the organ 116 homogenate suspension on 6 selective 7H11 agar plates. 2. culturing in 5 ml of selective 117
Kirchner liquid medium (21) by the addition of polymyxin B 200 U/ml, carbenicillin 100 118 mg/l, trimethoprim 20 mg/l and amphotericin B 10 mg/l (Selectatab, Mast Diagnostica GmbH) 119 for 4 weeks with subsequent sub-culturing of the entire culture onto Löwenstein-Jensen slopes 120 for a further 4 weeks and 3. resuscitation of persistent bacteria by culture filtrate. Kirchner 121 liquid medium was used to isolate different species of mycobacteria from human specimens. 122 Mitchison et al (21) showed that liquid Kirchner medium, made selective by the addition of the 123 antimicrobials, was more effective in the isolation of mycobacteria than other media tested. 124
Culture negative organs were defined as no colonies grown on 7H11 agar plates and no growth 125 in selective Kirchner liquid medium following inoculation on Löwenstein-Jensen slopes. 126
Immediately after termination of 14 weeks of chemotherapy, the remaining mice were 127 administered 0.5 mg/mouse of hydrocortisone acetate by daily oral administration for 8 weeks 128
to suppress host immunity, followed by CFU counting from lungs and spleens to determine 129 disease relapse. 130
Resuscitation of M. tuberculosis in mouse lungs and spleens. For resuscitation of M. 131 tuberculosis grown in mouse organs, culture filtrates containing RPFs were used as described 132 previously (15) (16) (17) . 133 days until an optical density of 1 to 1.5 was reached. The culture supernatants were collected 135 by centrifugation at 3000 g for 15 minutes and sterilized by double filtration with 0.2 µm filters 136 (Sartorius). The sterilized culture filtrates were made selective by the addition of polymyxin B 137 200 U/ml, carbenicillin 100 mg/l, trimethoprim 20 mg/l and amphotericin B 10 mg/l 138 (Selectatab, Mast Diagnostica GmbH) and immediately used for broth dilution to count the 139 most probable number (MPN) of the bacilli (22) . 140
Broth counting of lungs and spleens was performed as serial 10-fold dilutions in which 0.5 ml 141 of tissue homogenates were added to 4.5 ml of the culture filtrates. At 10-day intervals over a 142 2-month period of incubation at 37°C, the broth cultures were examined for visible turbidity 143 occurring exponential replication and death rates cannot be differentiated with this type of data, 153 a "knet" exponential rate constant was estimated separately before treatment began 154 ("knet_no_drug" where it would take a net positive value) and during treatment 155 ("knet_with_drug" where it would take a net negative value). During therapy, knet is a 1 st order 156 elimination rate constant which can be interpreted as the slope of the modelled line fit through 157 the logarithmic-transform of the data (with units in these data of wk -1 ). Parameter estimation 158 was carried out with nonlinear regression using the nonlinear least squares optimisation 159 function "lsqnonlin" as part of the "pracma" package in the R statistical software language, 160 with an objective function weighted by 1/(predicted value)^2. Standard errors of parameter 161 estimates were calculated using the method descripted previously (24) with the Jacobian of 162 model parameter sensitivities estimated using a numerical central difference method. The 163 datasets comprised from multiple individual subject animals were treated as a naïve pool for 164 data analysis purposes (25) rather than using the average of the data at each time-point. The 165 significance of differences between model parameter estimates under different therapies was 166 examined with pairwise Z-tests incorporating a Bonferroni correction of 3, where P values 167 ˂0.017 would be considered significant. The significance of differences between the relapse 168 rates was determined with pairwise Fisher's exact tests also with a Bonferroni correction of 3, 169
with P values ˂0.017 considered significant. 170
RESULTS 172
Treatment with moxifloxacin containing regimens in the Cornell mouse model. In the 173
Cornell model, after three weeks of infection, mean CFU counts in the organs reached log 7.54 174 in lungs and 6.99 in spleens (Table 2) . 175
When we investigated the substitution of moxifloxacin for either isoniazid or ethambutol in the 176 current drug regimen on the rate of bacterial CFU elimination, we found that the early 177 bactericidal activities were similar amongst the three drug regimens, which were 99% kill at 178 2.2 weeks for moxifloxacin replacing isoniazid regimen (RMZE), 2.7 weeks for standard 179 regimen (RHZE) and 3 weeks for moxifloxacin replacing ethambutol regimen (RHZM). 180
Treatment with RMZE increased the rate of bacterial elimination showing undetectable CFU 181 counts at 11 weeks compared to 14 weeks for the standard regimen and moxifloxacin replacing 182 ethambutol regimen (Table 2) . 183
These observations coincided with bactericidal activities as assessed using the mono-184 exponential bacterial elimination rate constants (Fig 1, and Table 3 ) where the exponential rate 185 constants (logarithmic base 10) for net bacterial elimination during treatment (k net_with_drug ) for 186 standard, moxifloxacin replacing ethambutol and moxifloxacin replacing isoniazid regimens 187 were -0.46, -0.50 and -0.65, in lungs and -0.46, -0.46 and -0.60 in spleens, respectively (Table  188 3). The higher the absolute value of this elimination rate constant (i.e. the steeper the slope of 189 the elimination on the logarithmic scale with units of wk -1 ), the quicker the exponential 190 elimination rate of CFU counts in the organs These values indicate therefore that compared to 191 the standard therapy, substitution of moxifloxacin for isoniazid gives a significant increase in 192 bacterial elimination in both lungs and spleens while substitution of moxifloxacin for 193 ethambutol makes a statistically indistinguishable difference. 194
In the CFU count free organs, no tubercle bacilli were recovered which was determined by 195 negative cultures of the organ homogenates in selective Kirchner broth for 4 weeks followed 196 by growth on Löwenstein-Jensen medium. Table 5 , treatment with the standard regimen RHZE gave rise to positive organs in 19 out of 212 21 mice (90% relapse rate) and RHZM led to 95% relapse rate after 14 weeks of treatment. In 213 contrast, treatment with RMZE resulted in 59% of relapse (P = 0.03 vs. RHZE, P = 0.009 vs. 214 RHZM, P < 0.017 significant at 0.05 level after Bonferroni correction for 3 pairwise 215 comparisons). 216
We also measured CF-dependent bacilli using culture filtrates in the organs which 217 showed CFU count negative after 8 weeks of steroid treatment. As shown in 
Moxifloxacin-replaced drug regimens are ineffective against CF-dependent tubercle 234
bacilli. The greater therapeutic efficacy and lower relapse rates achieved with moxifloxacin-235 isoniazid replacement regimen, as compared to the standard regimen, in this study is consistent 236 with previous reports (5-8). De Groote et al demonstrated that moxifloxacin replacing isoniazid 237 in the standard regimen gave rise to 63% disease relapse (6). In other studies, Nuermberger and 238 colleagues showed that the same drug regimen produced a lower disease relapse at 33.3% (7). 239
Late studies using two pathologically distinct murine tuberculosis models demonstrated very 240 similar low disease relapses (8). Our study confirmed this interesting observation showing 56% 241 relapse, indicating the consistency of the drug regimen in different mouse models. 242
The underlining mechanisms that moxifloxacin replacing isoniazid was more efficacious than 243 the standard or moxifloxacin replacing ethambutol regimens were unknown. It has been shown 244 previously that when mice were treated with rifampicin-isoniazid-pyrazinamide, rifampicin-245 isoniazid or rifampicin-pyrazinamide for 6 months, rifampicin-pyrazinamide treated group 246 demonstrated significantly lower relapse rates than the other two groups containing isoniazid 247 (26), suggesting that isoniazid antagonized the actions of rifampicin-pyrazinamide (26). It is 248 possible that replacement of isoniazid with moxifloxacin eliminated the antagonistic drug 249 interaction leading to the rapid organ CFU count clearance in mice. 250
The use of CFU counts as an end point reflects the clinical observations in patients to a large 251 degree, which is related to clinical endpoints such as sputum culture conversion in patients (3, 252 27, 28) . The improved efficacy with moxifloxacin replacement for isoniazid compared to the 253 standard regimen reflected the clinical outcome in patients to some extent, for example, the 254 moxifloxacin-isoniazid substitution regimen showed an effective bactericidal activity which 255 was able to kill CFU count positive bacilli faster than the standard regimen, leading to the 256 higher sputum culture conversion rate in humans (3, 27, 28) . standard regimens for treatment duration and disease relapses (3, 4) ; the underlying mechanism 279 is unclear. An important finding of the REMoxTB trial is that there was a proportion of 280 patients who showed sputum conversion quickly but continued to relapse after treatment with 281 all three drug regimens (9). Our experiments suggest that the high relapse rates may have been 282 due to CF-dependent bacilli (9) which, till now, have remained undetectable using 283 conventional culture methods, including those used in the clinical trials (3, 4, 9). Persistent 284 bacteria are established causes of prolonged chemotherapy and disease relapse (10). It has been 285 repeatedly shown that in the Cornell mouse model, high relapse rate after treatment with the 286 standard drug regimen was due to the presence of CF-dependent persistent bacteria (16, 17) . 287
Recently, we showed that drug regimens containing high doses of rifampicin (30 mg/kg or 288 higher) could eliminate CF-dependent persistent bacilli, which led to shortened treatment 289 duration from 14 weeks to just 6 weeks, without disease relapses (16, 18) . The lesson learnt 290 from the REMoxTB trial is that more rapid culture conversion in the short moxifloxacin 291 containing regimens may not allow for shortened regimens due to the presence of persistent 292 bacteria (9). A previous study also showed that early bactericidal activities of certain novel 293 drug regimens were not necessarily predictive of any sterilizing effects (29). This may be 294 attributed to the inability of the drug regimens to eliminate the persistent bacilli which were 295 undetectable using the traditional microbiological methods. Therefore, in addition to the 296 conventional microbiological methods, evaluation of anti-TB regimens by assessing their 297 efficacies in eliminating RPF-dependent M. tuberculosis is important for providing a 298 comprehensive profile of novel drug regimens before proceeding to human clinical trials. The 299 combined data sets on CFU counts, broth growth and persister counts will strengthen any 300 claims to be made on a regimen, which will ultimately increase the confidence of advancing it 301 into humans. that RPF-dependent persisters may be a novel and important clinical therapeutic target. a. Elimination rate constant equivalent to "knet_with_drug" b. P = 0.008 RMZE vs. RHZE, P = 0.065 RMZE vs. RHZM, P = 0.384 RHZE vs. RHZM c. P = 0.018 RMZE vs. RHZE, P = 0.011 RMZE vs. RHZM, P = 0.943 RHZE vs. RHZM P < 0.017 significant at 0.05 level after Bonferroni correction for 3 pairwise comparisons.
